Trial Outcomes & Findings for Clinical Impact of Cardiac Photon-Counting Detector CT (NCT NCT05240807)

NCT ID: NCT05240807

Last Updated: 2026-06-12

Results Overview

Percent area stenosis (PAS) measures coronary artery stenosis (blockage) and is defined as the vessel's cross-sectional area in the region of highest stenosis (i.e., most closed) divided by the healthy vessel's cross-sectional area. PAS can range from 0% to 100% with higher percentages indicating worse stenosis. In arm 1, PAS was measured at the site of worst stenosis in each coronary vessel or patient using validated commercial software. For each stenosis, PAS was measured at the same location in the photon-counting detector CT (PCD-CT) angiography scan and in the clinical CT angiography scan (EID-CT). These values were subtracted to get a change in PAS between the clinical EID-CT scan and the PCD-CT scan for each stenosis. Change in PAS impacts patient management. During recruitment, the PCD-CT scanner had a multi-energy ultra-high resolution update allowing a new scan mode that collected x-ray energy data. This mode was used for all patients recruited after the update.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

276 participants

Primary outcome timeframe

Through completion of CT exam, approximately 1 hour

Results posted on

2026-06-12

Participant Flow

Patients scheduled for a clinically indicated coronary CT angiogram, stress cardiac MRI, or nuclear cardiovascular stress scan in Mayo Clinic Rochester outpatient practice were invited to participate in this study from August 2022 to February 2026. After their clinical exam, patients were approached by a study coordinator to discuss the research study. If they provided written informed consent, the patient was escorted to their photon-counting detector CT scan.

After their clinical scan and before their research scan (intervention), 25 patients withdrew consent, 4 patients failed to meet the inclusion criteria, and 1 patient had an issue with IV placement that prevented scanning resulting in a final cohort of 246 patients.

Participant milestones

Participant milestones
Measure
Clinical Nuclear Medicine or MRI Cardiac Stress Test Cohort
Subjects scheduled for a clinically indicated nuclear medicine or MRI cardiac stress test received a research contrast-enhanced coronary CT angiogram using photon-counting detector CT at rest and after administration of a cardiac stress agent.
Clinical Coronary CTA Cohort
Subjects scheduled for a clinically indicated coronary CT angiogram received a research contrast-enhanced coronary CT angiogram using photon-counting detector CT.
Overall Study
STARTED
11
235
Overall Study
COMPLETED
11
235
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Clinical Impact of Cardiac Photon-Counting Detector CT

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Clinical Coronary CTA Cohort
n=235 Participants
Subjects scheduled for a clinically indicated coronary CT angiogram received a research contrast-enhanced coronary CT angiogram using photon-counting detector CT.
Clinical Nuclear Medicine or MRI Cardiac Stress Test Cohort
n=11 Participants
Subjects scheduled for a clinically indicated nuclear medicine or MRI cardiac stress test received a research contrast-enhanced coronary CT angiogram using photon-counting detector CT at rest and after administration of a cardiac stress agent.
Total
n=246 Participants
Total of all reporting groups
Age, Continuous
66.62 Years
STANDARD_DEVIATION 12.61 • n=9 Participants
71.64 Years
STANDARD_DEVIATION 7.06 • n=27 Participants
66.85 Years
STANDARD_DEVIATION 12.45 • n=267 Participants
Sex: Female, Male
Female
89 Participants
n=9 Participants
2 Participants
n=27 Participants
91 Participants
n=267 Participants
Sex: Female, Male
Male
146 Participants
n=9 Participants
9 Participants
n=27 Participants
155 Participants
n=267 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
n=9 Participants
0 Participants
n=27 Participants
1 Participants
n=267 Participants
Race (NIH/OMB)
Asian
6 Participants
n=9 Participants
0 Participants
n=27 Participants
6 Participants
n=267 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=9 Participants
0 Participants
n=27 Participants
0 Participants
n=267 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=9 Participants
0 Participants
n=27 Participants
3 Participants
n=267 Participants
Race (NIH/OMB)
White
221 Participants
n=9 Participants
11 Participants
n=27 Participants
232 Participants
n=267 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=9 Participants
0 Participants
n=27 Participants
0 Participants
n=267 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants
n=9 Participants
0 Participants
n=27 Participants
4 Participants
n=267 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants
n=9 Participants
0 Participants
n=27 Participants
3 Participants
n=267 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
228 Participants
n=9 Participants
11 Participants
n=27 Participants
239 Participants
n=267 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
4 Participants
n=9 Participants
0 Participants
n=27 Participants
4 Participants
n=267 Participants
Weight
87.55 kg
STANDARD_DEVIATION 17.73 • n=9 Participants
95.02 kg
STANDARD_DEVIATION 21.38 • n=27 Participants
87.89 kg
STANDARD_DEVIATION 17.93 • n=267 Participants

PRIMARY outcome

Timeframe: Through completion of CT exam, approximately 1 hour

Population: To compare PAS, PCD and EID-CT scans are needed so only arm 1 participants were analyzed in this measure. 235 participants were enrolled in arm 1, however 139 participants were analyzed as this outcome measure only pertains to the subset of patients with evaluable, calcified stenosis (i.e., low motion artifact, visible in both scans). Arm 1 was split into and analyzed in 2 groups due to a change in PCD-CT technology during recruitment (multi-energy ultra-high resolution update).

Percent area stenosis (PAS) measures coronary artery stenosis (blockage) and is defined as the vessel's cross-sectional area in the region of highest stenosis (i.e., most closed) divided by the healthy vessel's cross-sectional area. PAS can range from 0% to 100% with higher percentages indicating worse stenosis. In arm 1, PAS was measured at the site of worst stenosis in each coronary vessel or patient using validated commercial software. For each stenosis, PAS was measured at the same location in the photon-counting detector CT (PCD-CT) angiography scan and in the clinical CT angiography scan (EID-CT). These values were subtracted to get a change in PAS between the clinical EID-CT scan and the PCD-CT scan for each stenosis. Change in PAS impacts patient management. During recruitment, the PCD-CT scanner had a multi-energy ultra-high resolution update allowing a new scan mode that collected x-ray energy data. This mode was used for all patients recruited after the update.

Outcome measures

Outcome measures
Measure
Clinical Coronary CTA Cohort
n=139 Participants
Subjects scheduled for a clinically indicated coronary CT angiogram received a research contrast-enhanced coronary CT angiogram using photon-counting detector CT.
Clinical Nuclear Medicine or MRI Cardiac Stress Test Cohort
Subjects scheduled for a clinically indicated nuclear medicine or MRI cardiac stress test received a research contrast-enhanced coronary CT angiogram using photon-counting detector CT at rest and after administration of a cardiac stress agent.
Arm 1: Change in Clinical Coronary Artery Disease Status Measured in Photon-counting Detector CT Relative to Clinical CT as Measured by Percent Area Stenosis
Arm 1a (pre-multi-energy scanner update)
-6.7 Percent
Interval -8.0 to -5.5
Arm 1: Change in Clinical Coronary Artery Disease Status Measured in Photon-counting Detector CT Relative to Clinical CT as Measured by Percent Area Stenosis
Arm 1b (post-multi-energy scanner update)
-4.16 Percent
Interval -7.56 to -1.27

PRIMARY outcome

Timeframe: Through completion of CT exam, approximately 1 hour

Population: Perfusion defect analysis requires both nuclear medicine stress tests and photon-counting detector CT. Therefore, only arm 2 of the trial is included in this analysis.

Sensitivity was calculated as the number of patients correctly identified by the reader as having perfusion defects on photon-counting detector (PCD) CT divided by the total number of patients with perfusion defects. Specificity was calculated as the number of patients correctly identified by the reader as not having perfusion defects on PCD-CT divided by the total number of patients without perfusion defects. Sensitivity and specificity can range between 0 and 100%. All analyzed images were taken when the patient was at rest.

Outcome measures

Outcome measures
Measure
Clinical Coronary CTA Cohort
Subjects scheduled for a clinically indicated coronary CT angiogram received a research contrast-enhanced coronary CT angiogram using photon-counting detector CT.
Clinical Nuclear Medicine or MRI Cardiac Stress Test Cohort
n=11 Participants
Subjects scheduled for a clinically indicated nuclear medicine or MRI cardiac stress test received a research contrast-enhanced coronary CT angiogram using photon-counting detector CT at rest and after administration of a cardiac stress agent.
Arm 2: Reader Sensitivity and Specificity to Myocardial Perfusion Defects Imaged by Photon-counting Detector CT at Rest
Specificity
80 Percent
Arm 2: Reader Sensitivity and Specificity to Myocardial Perfusion Defects Imaged by Photon-counting Detector CT at Rest
Sensitivity
50 Percent

SECONDARY outcome

Timeframe: Through completion of CT exam, approximately 1 hour

Population: To compare CADRADS, PCD and EID-CT scans are needed so only arm 1 participants were analyzed in this measure. 235 participants were enrolled in arm 1, however 139 participants were analyzed as this outcome measure only pertains to the subset of patients with evaluable, calcified stenosis (i.e., low motion artifact, visible in both scans). Arm 1 was split into and analyzed in 2 groups due to a change in PCD-CT technology during recruitment (multi-energy ultra-high resolution update).

Coronary Artery Disease-Reporting and Data System (CADRADS) score is a value assigned to each patient based on the patient's highest percent diameter stenosis (PDS) with higher scores indicating worse stenosis. PDS is defined as the diameter of the stenosed (blocked) coronary vessel divided by the diameter of the healthy vessel. A CADRADs score of 0-5 is assigned to the following PDS values, respectively: 0%, 1-24%, 25-49%, 50-70%, 70-99%, and 100%. A CADRAD score was calculated for each patient in both EID-CT and PCD-CT scans based on the respective PDS for the same lesion. The number of patients whose CADRADS decreased in PCD-CT relative to EID-CT (e.g. 2 on PCD-CT, 3 on EID-CT) is reported below. Change in CADRADS impacts patient management. During recruitment, the PCD-CT scanner had a multi-energy ultra-high resolution update allowing a new scan mode that collected x-ray energy data. This mode was used for all patients recruited after the update.

Outcome measures

Outcome measures
Measure
Clinical Coronary CTA Cohort
n=139 Participants
Subjects scheduled for a clinically indicated coronary CT angiogram received a research contrast-enhanced coronary CT angiogram using photon-counting detector CT.
Clinical Nuclear Medicine or MRI Cardiac Stress Test Cohort
Subjects scheduled for a clinically indicated nuclear medicine or MRI cardiac stress test received a research contrast-enhanced coronary CT angiogram using photon-counting detector CT at rest and after administration of a cardiac stress agent.
Arm 1: Number of Participants With Decrease in Coronary Artery Disease-Reporting and Data System (CADRADS) Score
Arm 1a (pre-multi-energy scanner update)
19 Participants
Arm 1: Number of Participants With Decrease in Coronary Artery Disease-Reporting and Data System (CADRADS) Score
Arm 1b (post-multi-energy scanner update)
17 Participants

SECONDARY outcome

Timeframe: Through completion of CT exam, approximately 1 hour

Population: Perfusion defect analysis requires both nuclear medicine stress tests and photon-counting detector CT. Therefore, only arm 2 of the trial is included in this analysis.

Sensitivity was calculated as the number of patients correctly identified by the reader as having perfusion defects on photon-counting detector CT (PCD-CT) divided by the total number of patients with perfusion defects. Specificity was calculated as the number of patients correctly identified by the reader as not having perfusion defects on PCD-CT divided by the total number of patients without perfusion defects. Sensitivity and specificity can range between 0 and 100%. All analyzed images were taken after the patient was administered a pharmacological cardiac stress agent to increase heart rate.

Outcome measures

Outcome measures
Measure
Clinical Coronary CTA Cohort
Subjects scheduled for a clinically indicated coronary CT angiogram received a research contrast-enhanced coronary CT angiogram using photon-counting detector CT.
Clinical Nuclear Medicine or MRI Cardiac Stress Test Cohort
n=11 Participants
Subjects scheduled for a clinically indicated nuclear medicine or MRI cardiac stress test received a research contrast-enhanced coronary CT angiogram using photon-counting detector CT at rest and after administration of a cardiac stress agent.
Arm 2: Reader Sensitivity and Specificity to Myocardial Perfusion Defects Imaged by Photon-counting CT During Cardiac Stress
Sensitivity
83 Percent
Arm 2: Reader Sensitivity and Specificity to Myocardial Perfusion Defects Imaged by Photon-counting CT During Cardiac Stress
Specificity
40 Percent

Adverse Events

Clinical Coronary CTA Cohort

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Clinical Nuclear Medicine or MRI Cardiac Stress Test Cohort

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Cynthia McCollough

Mayo Clinic, Rochester

Phone: 507-284-6875

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place